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The physiology of the third stage of labour is described. Active management reduces the risk of  
postpartum haemorrhage, due to the use of a uterotonic agent. Intramuscular Oxytocin 10 IU has 
the highest efficacy and lowest side effect profile; although ergometrine, carbetocin and misoprostol 
are also effective. The appropriate uterotonic in different settings such as home birth by unskilled 
attendants, and at caesarean section is discussed. For the latter, there is less consensus on the 
optimal dose / route of oxytocin; this topic remaining on the research agenda. Delayed cord 
clamping enables transfusion of blood to the neonate and is recommended rather than early 
clamping. Controlled cord traction should only be performed by skilled birth attendants and confers 
minimal advantage in preventing retained placenta. The importance of early recognition of 
postpartum haemorrhage, and preparedness, is emphasised. An approach to medical and surgical 
management of postpartum haemorrhage is presented. 
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1.1 The third stage labour  
The third stage of labour is the time between the birth of the fetus and the expulsion of the 
placenta. Postpartum haemorrhage is traditionally defined as over 500mls blood loss. This can be 
further subdivided into primary (blood lost in the first 24hrs) or secondary (blood lost from 24hr to 6 
weeks), and into minor (500-1000mls) and major or severe (>1000mls) [1]. These definitions have 
been questioned due to the high prevalence of the 500mls loss especially at caesarean birth. 
Furthermore, whilst a blood loss of 500mls is unpredictable and usually caused by atony, the larger, 
life threatening blood losses of 1000 or 2000mls are far more predictable as they are mostly due to 
emergency CS, uterine rupture and placental abnormalities.[2] Thus, it is suggested that measures of 
PPH-related morbidity are used for the outcomes of clinical trials and audits.[3] 
The 500ml definition has been used to suggest the point at which PPH treatment should commence. 
However, the time at which midwives and doctors commence treatment appears to depend more 
on the speed of loss, underlying maternal risk factors, and clinical signs than volume.[4] This 
pragmatic approach, which tailors clinical PPH management to the individual, is appropriate so long 
as PPH treatment is initiated by 500mls in vaginal birth or 1000mls in a CS. Repeated studies 
demonstrate the inaccuracy of visual estimation, especially at higher blood loss volumes. Visual 
estimation can be improved by teaching and charts,[5] but it is recommended that blood loss 
volume is assessed using gravimetric assessment (weighing blood and approximating 1g weight to 
1ml of blood), supplemented with blood collection in a ‘V’ shaped drape.[6]   
1.2 Physiology of the third stage of labour 
1.2.1 Cord blood flow and effect of clamping 
In utero, fetal blood moves continuously between the placenta and the fetus with around 1/3 of the 
blood being in the placenta at any one time. The main channel is from the fetal heart down the 
aorta, through the paired umbilical arteries up the umbilical cord, through the placenta and back to 
the fetal heart down the umbilical vein. In the transition phase, immediately after birth, the fetus 
takes its first breath, drawing blood and air into its lungs and thus changing the pressure dynamics. 
The umbilical arteries also constrict. The combined effect is to draw blood into the fetus from the 
placenta, and halt the blood pumping out of the fetus into the placenta. In nature, this process 
would take some minutes as the baby draws blood from the placenta reservoir according to its 
needs. Newborns still attached to the placenta put onto scales immediately after birth slowly gain 
weight as they draw the blood in – but at a variable rate and volume.[7] 
Immediate cord clamping has two effects on the fetus. The abrupt blocking of the umbilical arteries 
retains blood in the fetus, but suddenly diverts blood flow to other body organs like the brain and 
kidneys. The blocking of the umbilical vein however, traps oxygenated blood in the placenta and 
prevents the fetal heart and lungs receiving the extra blood that they need. The combined effect of 
immediate cord clamping on the fetus is to reduce red cell mass, oxygenation, blood pressure, blood 



































































1.2.2 Placental detachment and retained placenta 
As with much of biological function, the third stage of labour is a thing of great wonder, managing to 
simultaneously both detach the placenta whilst blocking off the 500 mls/min blood flow to the 
placenta bed. In the 1990s, ultrasound studies allowed researchers to visualise the hidden process of 
the third stage for the first time.[9,10] This revealed, for the first time, that there were different 
phases of separation. In the first phase, the baby has left the uterine cavity, but the placenta 
remains attached to the uterine wall. The myometrium behind the placenta is thin and 
uncontracted, in contrast to the remainder of the uterus which is contracted and thickened. It is the 
duration of this first phase that largely determines the length of the third stage. The second phase 
starts when the retroplacental myometrium starts to contract, usually starting from the cervical end 
of the placenta.[11] The contraction of this retroplacental myometrium, as with any other muscle, 
leads to its shortening and thickening. This not only shears away the relatively inflexible placenta 
from the underlying myometrium, but also simultaneously obstructs the perforating radial arteries 
which carry the maternal blood to the underside of the placenta. This physiological ligature is the 
prime cause of haemostasis after childbirth and provides effective haemostasis even in women with 
marked clotting disorders. Conversely, any relaxation of this retroplacental myometrium will release 
the ligature and allow blood to once again flow through the radial vessels and cause postpartum 
haemorrhage. 
In the third phase the placenta is detached and squeezed through the cavity into the lower segment 
and out.  
Abnormalities of each of these phases can lead to retained placenta. If the retroplacental 
myometrium fails to contract then the placenta remains attached to it, and the this is known as 
placenta adherens. If the retroplacental myometrium contracts well, but expulsion of the placenta is 
prevented by a small area of placenta embedded deeply into the myometrium, then this is called 
partial accreta. If the placenta is both detached and expelled from the uterus, but remains in the 
lower segment, trapped behind a contracted cervix, then this is the relatively benign condition of 
trapped placenta. The three types are shown in figure 1. 
2. Routine care in the normal third stage of labour 
Active management of the third stage of labour (AMTSL) was originally introduced as a package to 
prevent PPH. Repeated studies have now shown the efficacy of AMTSL on third stage outcomes. 
Severe blood loss is reduced by nearly 70% and with it the rates of anaemia, transfusion and need 
for therapeutic uterotonics.[12] 
The main component of AMTSL was originally the uterotonic, with controlled cord traction to 
prevent trapping of the placenta. Early clamping of the cord was already routine care at that time 
that AMSTL was first introduced, but was hardly mentioned in the original reports.[13] Since then, it 
has become clear that it is only the uterotonic that has any meaningful effect on blood loss – 
controlled cord traction is largely unnecessary and early cord clamping appears harmful to the 
newborn.   
2.1 Umbilical cord clamping  
Although the WHO has long advocated deferred cord clamping (DCC; also known as ‘delayed’ or 


































































high quality trials are now available that clearly show how important that placenta blood transfer is 
for newborn and infant health. For the healthy term infant 3 minutes DCC leads to significantly 
higher haemoglobin for 6 weeks postnatally and iron stores for the first 3 months.[14] The 
importance of the improved iron stores for neurological development is seen in the long-term follow 
up studies. At 4 years of age children randomised to 3 minutes DCC had improved fine motor, social 
and communication skills.[15] And the importance of DCC appears to be greater in babies born 
prematurely or who need resuscitation at birth. Systematic review of 18 randomised trials show that 
DCC (of various lengths) in babies under 32 weeks reduces neonatal mortality by 32% and 
transfusion by 10%.[8] Clinical trials are more difficult in babies who need resuscitation, but a recent 
RCT from Nepal found that resuscitation with an intact cord led to improved neonatal oxygenation, 
higher APGAR scores, lower heart rate than those with immediate cord clamping.[16] Studies have 
used a variety of methods to facilitate placental transfusion: small bedside resuscitaires have been 
developed, whilst the transfusion can be accelerated through cord milking or lowering the baby 
beneath the level of the placenta. There is no good evidence to support one method over another. 
However, bedside resuscitation would appear to be optimal as it allows the transfusion to occur 
naturally at a pace dictated by fetal needs and prevents the enforced and psychologically traumatic 
separation of the baby from its parents.[17]    
2.2 Controlled cord traction 
Controlled cord traction (CCT) was originally introduced to prevent retained placenta as a 
complication of retained placenta use. This hypothesis was tested in a large WHO randomised trial 
which found minimal benefit of CCT when intramuscular oxytocin was used for prophylaxis.[18] It 
shortened the duration of the third stage but had no effect on rates of PPH or retained placenta. 
Around 6% of those in the ‘no CCT’ arm still required traction to deliver the placenta. 
Interestingly, in one of the study countries there was a significantly higher rate of retained placenta 
in the controlled arm. That country had a lot of service delivery problems, but had also continued to 
use intramuscular Syntometrine™ (oxytocin 5IU and ergometrine 500mcg) rather than oxytocin for 
prophylaxis. Thus, CCT, whilst unnecessary with oxytocin, may still be important in those who 
receive Syntometrine™ (or ergometrine alone as well, presumably) for prophylaxis. 
2.3 Uterotonics 
Oxytocin alone has been long-established as the leading uterotonic for prophylaxis. The use of a 
combined preparation of oxytocin 5iu and ergometrine 500mcg (Syntometrine™) has been popular 
in some countries, combining the immediate effect of oxytocin with the prolonged action of 
ergometrine. Randomised trials do suggest that it may be more effective than oxytocin alone, but at 
the ‘cost’ of relatively high rates of hypertension (1.7%) and nausea/vomiting (18%).[19] Thus, 
considering that the drug is being used in normal, healthy women, most of whom would not have 
had a PPH even without prophylaxis, there is a wide consensus to use the drug with the least side-
effects: oxytocin. 
It has been usual practice to administer prophylactic oxytocin intramuscularly. Recent randomised 
trials however demonstrate that oxytocin is more effective when administered intravenously (iv) 
than intramuscularly (im). In the Dublin randomised trial, women who received 10 units of oxytocin 
iv rather than im had half the rate of severe PPH rate and 70% less need for need for blood 


































































and those who were induced, groups which also had higher rates of PPH. Injecting just 3iu of 
oxytocin intravenously over 15 seconds causes a rapid, transient drop in blood pressure by 10-40% 
[21] and has been implicated in maternal deaths - so it was very reassuring that they saw no such 
effects in this study.  
Carbetocin, a synthetic long-acting version of oxytocin, had been hoped to provide the extended 
action of ergometrine without the side effects and studies using it iv for prophylaxis at CS had 
showed promise.[22] However, a large randomised trial of im heat-stable carbetocin versus im 
oxytocin has shown that there is absolutely no difference in efficacy between them.[23] The one 
potential benefit is that this new version of carbetocin is heat stable, which may increase the 
effectiveness ‘on the ground’ in settings where the reliability of the cold chain cannot be assured.   
Oral misoprostol tablets have been widely studied as an option for prophylaxis, but a large RCT 
found them less effective than oxytocin and with more side effects.[24] Some have combined it with 
oxytocin to achieve rapid but prolonged effects. A recent network meta-analysis of all randomised 
trials found that although Syntometrine™ and combined misoprostol + oxytocin are probably the 
most effective agents for prophylaxis, they are both associated with most side effects.[25] 
2.4 Conclusion 
The uterotonic is the most important component of AMTSL. Early cord clamping appears to be 
harmful and CCT is of little benefit (except possibly when ergometrine is a component of the 
uterotonic). The ideal uterotonic for prophylaxis is probably im oxytocin 10iu, as it combines efficacy 
with a low side effect profile. For those at higher risk, iv oxytocin (given slowly over at least 1 
minute) is probably the best option if given slowly as it has fewer side effects than oxytocin 
combined with ergometrine or misoprostol.  
Physiological management remains an option for those at low risk, especially where there is rapid 
access to effective treatment if needed. An attractive option is that of secondary prevention, where 
physiological management is combined with early treatment. This strategy reduces the number 
receiving prophylaxis by over 90% without obvious harm.[26] This targeted approach might be good 
option both for the mother and the health systems. Further larger studies are awaited to see the 
effect on rarer outcomes. 
3. Adapting third stage management for particular situations 
3.1. Adaptations of management for low resource settings 
The components of Active Management of Third Stage Labour (AMTSL) described in the previous 
section which includes intramuscular oxytocin, delayed cord clamping and controlled cord traction 
(CCT) may not all be feasible in low resource settings.[27] 
In such settings, many women deliver at home with traditional birth attendants (TBAs), who are not 
usually skilled in administering injections or performing controlled cord traction. In addition, many 
women deliver in primary care clinics which may not always have a professional nurse on duty with 
the requisite skill. Oxytocin may not consistently be available due to poor functioning of the cold 
chain since it requires refrigeration.  
In such settings, it is therefore often necessary to modify management of the third stage. The need 
for delayed cord clamping is particularly important to reduce infant anaemia in the context of 


































































tetanus which remains a cause of newborn mortality in some countries.[29] Similarly, there is an 
imperative to prevent PPH due to high prevalence of maternal anaemia from undernutrition and 
communicable diseases such as malaria, as well as a higher risk of maternal mortality.[30] 
In such settings the following is recommended: 
 Early suckling of the baby on the breast to promote physiological oxytocin release. 
 Administration of a suitable uterotonic to contract the uterus after the birth of the baby.  
Several alternatives to standard im oxytocin have been shown to be effective in reducing 
PPH compared to placebo[25,31]: 
- The Uniject device is a pre-assembled syringe unit with 10 IU oxytocin that TBAs can 
administer, the disadvantage being the logistics of distribution, refrigeration and 
disposal of devices.[32]  
- Oral Misoprostol 400 to 600 mcgms. Currently the latter is available, affordable, heat 
stable and easy to administer. There are case series of its use by TBAs, and also of 
self-administration by women who were supplied the medication at an antenatal 
clinic visit.[33,34,35] 
- Heat stable carbetocin has potential value due to the lack of cold chain requirement 
but requires skill with injection which would be available in most level of 
facilities.[23] However, for use by TBAs at home, pre-assembled syringe devices 
similar to the Uniject would need to be manufactured. 
 Delayed cord clamping. 
 Cutting the cord with a sterile instrument. Several TBA training programmes supply them 
with delivery kits which include a sterile razor blade and sterile threads to tie the cord. 
Again, women attending antenatal clinics can be supplied with such kits in the event of 
home birth. Of note, routine tetanus immunisation during antenatal care has assisted in the 
reduction of neonatal tetanus in low resource settings.[29] 
 Passive delivery of the placenta. CCT should not be employed by non-skilled attendants in 
home birth due to the associated risk of cord snapping or uterine inversion. It is a skill that 
trained midwives should have and can be performed at primary care clinics staffed by such 
personnel.[28] 
3.2 Management issues at Caesarean Section (CS) 
The same principles of management of the third stage after vaginal delivery apply to caesarean 
section, notably use of uterotonic drugs to contract the uterus, delayed cord clamping and CCT for 
placental delivery. In addition, skin to skin contact and early suckling to aid uterine contraction, can 
be performed at CS. This can only occur for uncomplicated CS under regional anaesthesia. The three 
elements of management will be described separately:  
 Administration of uterotonic. Oxytocin is the preferred prophylactic uterotonic, although it is 
acknowledged that most of the research has been for vaginal delivery rather than CS.[25,31] 
The precise dose and route of administration remain contentious. During CS, there is iv 
access and the anaesthetist (doctor or other health care worker providing anaesthesia) 
administers medications according to instruction from the surgeon or anaesthetic protocol. 
The recent WHO guidance states that 10 IU oxytocin should be administered iv or im 
[31]. However, oxytocin causes hypotension following rapid iv boluses. In some cases, this 


































































existing hypovolaemia may have contributed to fatality.[36] The pharmacokinetic research 
demonstrates that the lowest dose of oxytocin iv bolus which is effective to contract the 
uterus is less than 5IU and such doses have less hypotensive effect.[36] The recent WHO 
guidance qualifies its recommendation for 10 IU im/iv by indicating that, at CS, consideration 
should be given to dividing the 10 IU dose into a smaller iv bolus accompanied by an 
infusion. This is also the protocol in SA where 2.5 IU are given by slow iv bolus and the 
remaining 7.5 IU by infusion.[37] The RCOG green top guideline specifies 5IU IV (RCOG 
2016).[38] Guidance varies also about the dose placed in an infusion from 5 IU to 40 IU. 
Prophylactic oxytocin Infusions have been less researched but are recommended by many 
guidelines for the duration of the actual surgery, and for continuation in the postnatal ward 
after the patient leaves theatre to maintain uterine contraction.   
Previous anaesthetic publications recommended ‘the rule of 3’: 3IU iv after delivery 
of baby, followed by additional 3 IU if poor uterine contraction, and 3 IU in the drip as an 
infusion.[39,40] However, a recently published new international consensus statement by an 
association of obstetric anaesthetists recommended 3 IU iv at intrapartum CS but only  I IU 
at elective CS, in both cases accompanied by infusions  from 3 to 15 IU.[41]  
There is minimal research on im administration of oxytocin or other uterotonics at 
CS which may be the optimal route (deltoid injection); this route may minimise hypotension 
effects whilst maintaining uterine contraction.[37] 
Carbetocin, ergometrine and syntometrine have a more prolonged action than 
oxytocin and this may be valuable to reduce post CS bleeding from uterine atony after the 
patient has left theatre. Like oxytocin, all also have side-effects with rapid iv injection. 
There are a few small trials where tranexamic acid (TXA) has been administered at 
CS together with standard uterotonic for PPH prophylaxis with some success; this needs to 
be explored further.[42] The WOMAN trial which was the largest one to investigate TXA for 
efficacy and thrombotic side effects, was for vaginal delivery but not CS, for which 
thrombotic risk is intrinsically greater.[43] 
In summary, although there is agreement that an uterotonic agent is necessary to 
prevent PPH at CS, and that oxytocin is the drug of choice; there is a need for consensus 
amongst obstetricians and anaesthetists on the safe effective dose and routes. It is an area 
for further multidisciplinary research involving anaesthetists and obstetricians.   
 Delayed cord clamping.  Similar to guidance for vaginal delivery, delayed cord clamping is 
recommended.   
 Controlled cord traction to deliver the placenta. This is recommended in preference to 
manual removal of placenta, the latter being associated with increased blood loss.[28,44] 
3.3 High risk birth 
The management of third stage of labour needs to be adjusted in certain situations and a risk 
assessment is necessary to identify such scenarios.  
 Women at increased risk of PPH after delivery.[38] This includes: grand multiparity, previous 
PPH, multiple pregnancy, prolonged labour, chorioamnionitis, abruptio placentae, operative 
vaginal delivery etc. Whilst there is minimal evidence for additional PPH prophylaxis in such 
cases, it is reasonable to consider this by, for example administering a 20 IU oxytocin 
infusion in combination with the standard oxytocin prophylaxis. The Gallos network analysis 


































































such as ergometrine, or misoprostol can be considered as alternative prophylactic adjuncts, 
provided not contra-indicated.[25] Women with severe anaemia prior to delivery may also 
be considered for additional PPH prophylaxis. 
 Women suspected to have a morbidly adherent placenta at CS. Controlled cord traction is 
avoided and if spontaneous delivery of the placenta does not occur, the placenta may be left 
in situ or consideration given to hysterectomy as dictated by the clinical situation.[45] 
 Women with cardiac conditions especially fixed output conditions such as tight mitral 
stenosis. Lithotomy position must be avoided, and meticulous monitoring of fluid balance is 
required to prevent pulmonary oedema.[46] Ergot derivatives for preventing or treating PPH 
must be avoided. Nevertheless. uterotonics in the form of low dose oxytocin are important 
to prevent PPH.[47] 
 
4. Dealing with complications 
4.1 Third stage complications  
Maternal complications associated with the third stage of labour after vaginal delivery include 
uterine atony, genital tract trauma, retained placenta (or placental fragments) and uterine inversion; 
all of which can cause PPH and also predispose to uterine sepsis. At CS, PPH may be due to uterine 
atony, trauma including rupture, adhesions, and placental problems (praevia, morbid adherence 
etc).  Although rare, amniotic fluid embolism causing severe coagulopathy is another cause of PPH. 
PPH is estimated to occur in 6.6% of deliveries and is a major cause of maternal mortality globally 
accounting for 27.1 % of maternal deaths.[48] Mortality is higher in low resource settings due to 
both an increase in PPH incidence and case fatality rate.[30] PPH also contributes to significant 
morbidity in all settings as evidenced by Severe Acute Maternal Morbidity or Near Miss studies.[49]    
4.1.1 Postpartum haemorrhage after vaginal delivery 
This chapter will not provide details of PPH management which can be found in a previous dedicated 
edition on PPH (November 2019). A summary is provided in figure 2. Whereas there is high quality 
evidence for medical treatment of PPH with uterotonics or TXA; there is a dearth of such evidence 
for many of the mechanical or surgical measures and the sequence in which they should be 
employed. Most protocols or guidance are based on review of case series, mortality audit findings 
and expert opinion. 
Important features of management include: 
 Recognition of excessive blood loss. Blood loss is often underestimated and signs of shock 
such as reduction in blood pressure may only occur after 1.5 to 2 litres blood loss. This 
means that active treatment starts ‘too late’ when coagulopathy has developed, and all 
known treatment measures are more difficult to enact. Late recognition of the extent of 
blood loss is compounded when bleeding may be concealed such as in abruptio placentae or 
paravaginal haematomas. 
 Adequate resuscitation with crystalloids, colloids and blood products.[50] 
 Performing initial measures such as emptying bladder, oxytocin infusion and bimanual 
compression whilst awaiting more experienced help. 


































































 Stepwise treatment of the identified cause with progression from medical measures  
(uterotonics, TXA) to first aid measures such as bimanual or aortic compression and non-
pneumatic anti-shock garment (NASG) to surgical measures (removal of placenta, repair of 
genital tract  tears, examination in theatre, balloon tamponade, laparotomy with 
compression sutures, artery ligations, uterine artery embolisation (UAE) or hysterectomy as 
a last resort) as required and without delays.[51,52,53] In the rare case of uterine inversion, 
immediate replacement of the uterus followed by oxytocin infusion is required.  
 Team work with a team leader, participants knowing their role and sufficient personnel to 
perform the multiple actions required.[54] 
 Addressing the woman and her family with respect to inform them of the situation and 
reassure them that you are providing her with lifesaving treatment 
 Addressing specific problems related to low resource setting where there may be a lack of 
skilled personnel, non - availability of blood products, lack of specialist radiology or 
haematology services, and a need to refer such patients to higher levels of care with 
resultant delays which can be fatal.[27] The NASG has been documented to decrease 
mortality when applied before/during transport and to stabilize women to overcome delays 
due to the problems in low resource settings.[55] 
4.1.2 Prolonged third stage 
Third stage is said to be prolonged if the placenta is undelivered within 30 minutes with AMTSL and 
60 mins with physiological management. It may be due to entrapment of a detached placenta at the 
level of the cervical os (‘trapped placenta’) in which case it requires a simple manual removal. 
However, if the placenta is still attached to the uterine wall (‘placenta adherens’) it requires a full 
manual removal with the attendant’s hand placed high into the uterus to detach the placenta from 
its site. This is normally an uncomplicated procedure but, if morbidly adherent (‘partial accreta’), can 
lead to difficult removal and massive bleeding (see figure 1). 
Numerous studies have been conducted to examine the efficacy of the injection of oxytocin into the 
umbilical vein but have found no consistent benefit.[56] 
In the absence of PPH, attempts to remove the placenta can be done at 30 mins or 60 mins 
according to the definition above. However, in the presence of PPH urgent removal is required and 
the steps outlined above should be followed. 
 
4.1.3 Bleeding at CS 
PPH at CS is most commonly defined as blood loss equal or greater than 1000mls, since blood loss at 
CS is intrinsically greater than after vaginal delivery. It can be due to uterine atony, surgical 
adhesions, uterine tears, bleeding from the placental site in cases of placenta praevia or morbidly 
adherent placenta, and amniotic fluid embolism. The combination of anterior placenta praevia with 
previous lower segment CS increases the risk of morbidly adherent placenta considerably. 
The ASOS study, a WHO systematic review and mortality audits from some countries have all shown 
high case fatality rates from CS particularly in low resource settings. These studies also demonstrate 


































































Similar to PPH after vaginal delivery, the evidence base for medical management of PPH at CS is of 
much higher quality than that for surgical modalities of treatment.  
Important features of management include: 
 Recognition of PPH. This is problematic at CS due (a) to contamination of blood with liquor 
making it difficult to assess blood loss, (b) falls in BP being misinterpreted as an effect of 
regional anaesthesia, (c) blood loss from the uterus coming out of the vagina under the 
surgical drapes may not be appreciated, and (d) importantly after abdominal closure, 
internal CS bleeding into the peritoneal cavity may not be recognised until much blood has 
been lost 
 Active and effective resuscitation usually done by the anaesthetist who needs to 
communicate with the surgeon about the patient’s condition 
 Identifying the cause of the bleeding; posterior uterine tears can be missed, as can bleeding 
from adhesions during wound closure 
 Medical and surgical modalities as described under PPH after vaginal delivery, with early 
recourse to uterine compression suture for intractable uterine atony, and other surgical or 
radiological measures.[52] 
 Ensuring thorough assessment of vital signs and signs of bleeding after CS in a staffed 
recovery area so that if any signs, she will not be signed out to a ward but returned to 
theatre,  
 Addressing specific problems related to low resource setting which are similar to those 
described above. Specifically, for CS, there is unlikely to be facilities for UAE and at district 
hospitals no one availability with skill for hysterectomy. The uterine tourniquet, compression 
sutures, and packing before closing and referring to higher level of care will then be 
necessary. When bleeding occurs post  CS when the woman is in recovery or on the ward, 
the NASG can provide stabilization while waiting to return to the surgery or transfer to 
higher level of care. 
4.2 Ensuring preparedness for third stage management and emergencies  
In order to perform appropriate evidence-based management of the third stage of labour, facilities 
should follow a defined protocol, all staff should be trained and supplies should be available. In 
addition, this should apply to management of third stage complications which are mostly 
emergencies.  
Training  
Active and passive management of the third stage of labour should be taught at undergraduate level 
to student doctors and nurses and be an essential competency for all. Similarly, management of 
third stage emergencies, notably PPH, should be part of this training. In the workplace drills/scenario 
training should be conducted regularly to maintain competencies and ensure preparedness for 
emergencies.[58] In situations where many women deliver at home with a TBA or equivalent in 
attendance, they require training to provide a uterotonic such as misoprostol, to recognise PPH and 
retained placenta, and perform preliminary measures for PPH such as  emptying the bladder, 
administering misoprostol, and baby suckling.[59] 


































































Oxytocin needs to be available and refrigerated, requiring an effective cold chain. However, facilities 
need alternative uterotonics and TXA, for sequential management of PPH. At primary care level, a 
PPH box containing uterotonic drugs, resuscitation fluids, iv infusion sets, blood collection bottles 
and urinary catheters, enables more efficient management when an emergency occurs. The 
introduction of PPH care bundles need intervention studies to evaluate effectiveness.[60] 
Operational managers of ward areas need to ensure that supplies are available and accessible. Blood 
product availability will vary according to the type of facility. Larger regional and tertiary hospitals 
are likely to have blood banks with a full range of blood products. District hospitals and many 
regional hospitals will have un-crossmatched packs of O negative and O positive blood stored in a 
fridge which can be administered rapidly for a severe PPH. In such settings the use of fresh dried 
plasma which is a pharmacy shelf item acts as a source of clotting factors. Some African countries 
such as Rwanda, Ghana and SA are utilising drones to fly blood products to remote areas 
WHO Surgical Safety Obstetric Checklist. 
Running the multidisciplinary check list at CS, before anaesthesia, before surgical incision and before 
leaving theatre alerts personnel to potential risks at CS and encourages preparedness. There is some 
evidence that indicates reduction of adverse event when used.[61] 
Transport, referrals and clinical support  
In academic and tertiary level hospitals, junior staff can call a more senior experienced doctor to 
assist with an intractable complex PPH and initiate a ‘Massive Obstetric Haemorrhage’ response so 
the multidisciplinary team can be assembled. However, in many low resource settings where care is 
tiered and organised around levels of care there are challenges. For example, a district hospital in a 
rural area would not have a specialist anaesthetist or obstetrician on site or available. The work 
would be performed by general doctors or non-doctor equivalents. This cadre can be trained to 
perform most of the procedures required for PPH short of hysterectomy, temporise the patient and 
then refer to the next level of care.  Balloon tamponade, and the uterine tourniquet placed at 
laparotomy together with active resuscitation and uterotonics are all measures that can improve 
condition prior to transfer.[62,63] On site ambulances would assist urgent referral and Air transport 
could assist in remote areas. There is evidence that the NASG assists in treating shock during 
transfer.[55]  TBAs need links with facilities and have mobile phones and working relations with 
nearest hospital for advice and urgent referrals.  
In summary, the health system and its staff need to be fully prepared and equipped to manage the 
third stage appropriately to prevent PPH and other complications. This includes TBAs performing 
home births in low resource settings. Preparedness for emergencies involves Scenario / drills 
training, ensuring availability of essential supplies, and ensuring clinical support mechanisms, 




































































The third stage of labour is the time between birth of the fetus and expulsion of the placenta, and 
involves uterine contraction, placental detachment and expulsion. Active management aims to 
prevent postpartum haemorrhage (PPH) whilst avoiding retained placenta, both complications 
associated with maternal mortality. Research shows that the most important component of active 
management is the uterotonic agent. The uterotonic of choice, with highest efficacy and lowest side 
effect profile is 10 IU intramuscular Oxytocin after vaginal birth, although ergometrine, carbetocin 
and misoprostol have all been shown to be effective in preventing PPH. Misoprostol is preferable in 
the context of home delivery by unskilled attendants with no refrigeration facility or skill for 
injection. At caesarean section, there is less consensus on the optimal dose and route of oxytocin 
with suggestions that the 10 IU be divided between lower dose slow intravenous injection and an 
infusion. Carbetocin, due to its prolonged action and heat stable formulation offers many benefits 
but currently is not widely available. Delayed cord clamping enables transfusion of blood to the 
neonate and is now recommended rather than early clamping. Controlled cord traction should only 
be performed by  skilled birth attendants and confers minimal advantage in preventing retained 
placenta, unless ergometrine was given as prophylactic uterotonic. The importance of early 
recognition of postpartum haemorrhage, and being prepared (ensuring availability of uterotonics, 
infusion fluids and blood, health workers with the necessary skills, and simulation training) is 
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Figure 2. Flow chart for PPH management showing first and second line management options. Text 




iv access, X-match, saline infusion
Bimanual compression (uterus empty)
Aortic compression (retained placenta)





















[Assess clotting at bedside]
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[Correct clotting abnormalities







Aortic compression if bleeding heavy
Manual removal of placenta
(cord traction if trapped placenta)

















• Iliac artery ligation
Hysterectomy
Laparotomy
(surgical options as for CS)
Postnatal after CS












 The normal third stage of labour depends on contraction of the retroplacental myometrium.  
 Routine management includes prophylactic uterotonics and delayed cord clamping (DCC) 
 At home birth, unskilled attendants can use misoprostol with DCC but without cord traction  







1. Although 10 IU intramuscular oxytocin is the preferred medication for active management of 
third stage labour, alternative routes and doses, or alternative medications must be 
considered in different settings such as at Caesarean section or home birth. 
2. Delaying cord clamping for 3 minutes has both short and long-term benefits for babies, 
especially those needing resuscitation.  
3. Intramuscular carbetocin is as effective as intramuscular oxytocin for PPH prophylaxis, and is 
being made available at low cost in a heat stable preparation for low income settings.  
4. All maternity facilities need to be prepared for third stage management and its 
complications by ensuring correct supplies, trained staff and regular scenario training  
*Practice Points
Research agenda 
1. What is the appropriate safe effective dose of uterotonic for PPH prophylaxis at Caesarean 
section? 
2. Does the use of an intrapartum oxytocin infusion reduce the efficacy of oxytocin prophylaxis 
and treatment, and is there a more effective alternative? 
3. Should additional prophylaxis be given to women assessed to be high risk for PPH after 
vaginal delivery? 
4. How can deferred cord clamping be optimised at birth in babies requiring resuscitation? 






1. For home delivery by an unskilled birth attendant, the following management for the third 
stage should be recommended : 
(a) No uterotonic agent should be given 
(b) Oral misoprostol can be administered 
(c) Delayed cord clamping 
(d) Controlled cord traction 
(e) Early suckling of the neonate 
Answers: (a) F, (b) T, (c) T, (d) F,  (e) T 
 
Explanation to the answers to question 1  
Network analysis demonstrates that use of several uterotonic agents individually (oxytocin, 
ergometrine, misoprostol, carbetocin) significantly reduce the risk of PPH  so  a uterotonic agent 
should be given at home birth by the birth attendant, with the chosen agent being one that can be 
safely administered in this setting.[25,31] 
Oral misoprostol can be administered in the home setting; it is easy to administer, does not require 
refrigeration and there are several studies where it has been employed in this context.[33,34,35] 
Delayed cord clamping has been shown to have benefit for the fetus and is practicable in low 
resource emergency settings. [8,16] 
Evidence shows minimal benefit from CCT, unless following ergometrine. It is a skilled procedure and 
it is recommended that it should not be performed by an unskilled birth attendant.[18,28] 
Early suckling at the breast stimulated endogenous oxytocin release which enable uterine 
contraction and is also beneficial for the neonate (skin to skin and enables breast feeding) 
 
2. At caesarean section for PPH prophylaxis: 
(a) Oxytocin can be administered intramuscularly 
(b) The placenta should be removed manually  
(c) Misoprostol is the medication of choice 
(d) There is no consensus on the appropriate does of intravenous oxytocin  
(e) Rapid iv boluses of oxytocin can cause maternal hypertension  
Answers: (a) T, (b) F, (c) F, (d) T, (e) F 
 
Explanation to the answers to question 2  
Network analysis shows im oxytocin is effective for preventing PPH in third stage and, although most 
research is on vaginal delivery, there is no pharmacological reason why it should not have same 
efficacy at CS.[25,37] One systematic review shows increased blood loss with manual placental 
removal compared to controlled traction after placental separation.[28,44] Network analysis shows 
oxytocin to be the uterotonic of choice in terms of efficacy and side effect profile.[25] Also, the 
parenteral route is indicated at CS, and misoprostol has no parenteral preparation. International 
obstetric guidelines and anaesthetic consensus documents differ on preferred route and dose of 
oxytocin.[31,38,39,40,41,46] Rapid iv boluses of oxytocin at CS have been shown by pharmacokinetic 
studies and in some case reports to cause maternal hypotension (not hypertension).[36] 
 
3. Studies have shown that the benefits of deferring cord clamping for 3 minutes include: 
(a) Reduced rates of PPH in the mother  
(b) A 10% reduction in mortality in healthy term babies born vaginally 
*MCQs
(c) Improved motor skills at 4 years of age in healthy term babies born vaginally. 
(d) A 30% reduction in mortality in premature babies 
(e) Improved Apgar scores in babies needing resuscitation 
Answers: (a) F, (b) F, (c) T, (d) T, (e) T 
 
Explanation to the answers to questions 3 
Deferred, or delayed cord clamping is now recommended by all major guidelines internationally. 
There appears to be no benefit to the mother, but the transfer of oxygenated blood to the baby in 
the first minutes after birth appears to have major effects on the baby. The oxygen in the placental 
blood improves oxygenation and resuscitation,[16] whilst the increased haemoglobin reduces infant 
anaemia. It is probably the improved iron stores (important for neurone growth) that leads to the 
improved neurological function seen in the long-term follow-up studies of babies randomised to 
early or delayed cord clamping.[15] The optimal delay is not known, but the studies showing 
improved long-term outcomes were all conducted using a delay of 3 minutes.[14] Randomised 
studies of delayed cord clamping in premature babies together show a 30% reduction in 
mortality.[8] The reason is likely to be a combination of improved oxygenation, improved blood 
pressure, a more stable transition to respiration, higher blood volume and haemoglobin. There are 
no studies that show an effect of delayed cord clamping on the neonatal mortality of healthy term 
infants. Neonatal mortality is very rare in this group, and so, even if there were to be a reduction in 
mortality with delayed cord clamping, it would take an enormous randomised trial to show it and 
this has not been done.  
 
4. Regarding placental detachment during the third stage of labour: 
(a) Ultrasound can be used to differentiate different types of retained placenta 
(b) Retained placenta is associated with use of ergometrine for PPH prophylaxis 
(c) Umbilical vein oxytocin injection is an effective treatment for retained placenta 
(d) The myometrium behind the placenta is the first part of the myometrium to contract 
(e) The use of controlled cord traction reduces maternal PPH when oxytocin is used for 
prophylaxis 
Answers: (a) T, (b) T, (c) F, (d) F, (e) F 
 
Explanation to the answers to questions 4 
The large WHO controlled cord traction study found no difference overall in PPH rates between 
those who had CCT and who didn’t in women given intramuscular oxytocin for 3rd stage 
management.[18] Intriguingly, however, there was a small subgroup who were mistakenly given a 
combination oxytocin/ergometrine in the study who needed the CCT to prevent retained placenta. 
This hints that CCT may be necessary in this subgroup. The ergometrine risk is supported by the 
Begley study in which women who had PPH prophylaxis with intravenous ergometrine and CCT had 
very high rates of retained placenta compared to those with physiological management.[64] 
Ultrasound studies have provided an insight into the mechanisms of retained placenta and show 
that the retroplacental myometrium is last part of the myometrium to contract, and results in the 
shearing off of the placenta. Failure of this area to contract is the cause of one of the three types of 
retained placenta, ‘placenta adherens’. Several studies have tried to deliver oxytocin to this area of 
the uterus by injecting oxytocin into the umbilical vein so that it reaches the myometrium through 
the placenta. Despite early promise however, large double-blind studies have been unable to 
replicate the results.[56] 
 
 
